At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 738 enrolled
Drug / intervention
lefamulin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia
In Brief
A Phase 3 clinical trial evaluating lefamulin and Moxifloxacin for Community Acquired Pneumonia. Completed, enrolled 738 participants across 155 sites in 20 countries.
Detailed Summary
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity Acquired Pneumonia
CountriesArgentina, Brazil, Bulgaria, Chile, Georgia, Hungary, Latvia, Mexico, Peru, Philippines, Poland, Romania, Russia, Serbia, South Africa, South Korea, Spain, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartAug 2016
Primary CompletionJan 2018
TodayJul 2026
First PostedJun 27, 2016
Enrollment StartAug 1, 2016
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.0 years ago
Interventions
lefamulindrug
antibacterial agent
Moxifloxacindrug
antibacterial agent